Resonant Clinical Solutions has acquired France-based Creapharm Bioservices from Myonex, expanding its European biobanking capabilities and specialized cryogenic storage for biotherapeutics, advanced therapy medicinal products (ATMPs), and biological samples. Creapharm provides liquid-nitrogen storage at temperatures as low as -196 °C, mechanical freezing, cold storage, GMP-compliant sample storage, and GDP-compliant custody for quality control. The transaction strengthens Resonant's support for complex clinical programs, including cell and gene therapy trials, as non-small-molecule drugs accounted for 46% of Phase I to III trials started in 2024, up from 38% five years earlier, according to an IQVIA study published in August 2025. Financial terms were not disclosed.